The German study followed an earlier retrospective UK study, which showed an increased risk for colorectal cancer in patients with type 2 diabetes receiving chronic insulin treatment. 6 In the latter study by Yang et al., no distinction was made between the different types of insulin or the effect of insulin dose. The hazard ratio (HR) of colorectal cancer associated with ≥ one year of insulin use was 2.1 (95% CI: 1.2-3.4). The odds ratio of developing colorectal cancer increased by 21% for each incremental year of therapy. This increase in risk is comparable to that of patients with familial colorectal cancer. Since there is no alternative to insulin therapy in patients with type 2 diabetes and failing beta-cell function, the recommendation from Yang et al. was to assess the cost-effectiveness of a more stringent colorectal cancer-screening programme among patients with type 2 diabetes receiving insulin.
The German study 1 reported by Hemkens et al. was a retrospective cohort study of 127 031 patients without any known malignancy who exclusively received human insulin or only one type of insulin analogue for the first time. The type of insulin analogue was restricted to the short-acting analogues insulin aspart or lispro and the long-acting analogue, glargine. The mean follow-up time was 1.63 years and the period of interest was between 1 January 2001 and 30 June 2005. During this period, malignant neoplasms were observed in 5 009 patients.
A positive association between cancer incidence and insulin dose was found for all insulin types. A dose-dependent increase in cancer risk was found for insulin glargine compared to human insulin in contrast with insulin aspart or lispro. The HR was 1.09 (95% CI: 1.00-1.19) for a daily dose of 10 IU, 1.19 (95% CI: 1.10-1.30) for a daily dose of 30 IU, and 1.31 (95% CI: 1.20-1.42) for a daily dose of 50 IU. The number needed to harm was 100 patients treated for a period of 18 months. 7 The authors admitted to the 'relatively fragile nature' of their data, and underscored the fact that their study results could not prove causality between glargine use and the increased risk of cancer. Hemkens et al. concluded that this issue should be investigated in a properly designed prospective study.
In the first of the three commissioned studies, Jonasson et al.
3 performed a retrospective study of 114 841 individuals in Sweden who received a prescription for insulin over a two-year period. They found that women who used insulin glargine as monotherapy had a relative risk (RR) of breast cancer of 1.97 (CI 95% CI: 1.29-3.00), compared to women who used an insulin other than insulin glargine, after adjusting for known confounders. The authors attributed this increase in risk of breast cancer to 'random fluctuation' and concluded that no definite conclusions regarding a possible causal relationship between insulin glargine use and the occurrence of malignancies could be drawn from the results of this study.
In the second of the commissioned studies, Currie et al. 4 performed a retrospective analysis of 62 809 patients with type 2 diabetes treated with four different regimens since 2000: metformin monotherapy, sulfonylurea monotherapy, sulphonylurea plus metformin, and insulin-based therapy. This study showed that metformin carried the lowest risk of cancer compared to no therapy (but failed to reach statistical significance to reduce cancer). Of these, 2 106 patients progressed to develop a solid tumour during the study period (an annual incidence of 1.1%). Compared to meformin, the adjusted HR for metformin plus sulphonylurea was 1.08 (95% CI: 0.96-1.21), while the HR for sulphonylurea monotherapy was 1.36 (95 CI: 1.19-1.54), and that for insulin-based regimens was 1.42 (95% CI: 1.27-1.60). Insulin therapy compared to metformin increased the risk of colorectal cancer (HR 1.69, 95% CI: 1.23-2.33) and pancreatic cancer (HR 4.63, 95% CI: 2.64-8.10) but did not increase the risk of breast or prostate cancer. The results for sulphonylureas were similar to those for insulin. In this study, the use of insulin analogues (including glargine) compared to human insulin was not associated with increased risk of cancer.
In the third commissioned study, 5 also retrospective, a twopronged approach was used to investigate the effect of insulin use on the incidence of cancer. In the first approach, a fixed cohort of 36 254 people with diabetes (19 899 definite type 2 patients) was identified in Scotland. They had received any type of insulin during the four-month period July to October 2003. This cohort was followed up until 31 December 2005. A total of 715 incident cancers occurred in this cohort (1.97%, 0.95 events per 100 person-years at risk).
After adjusting for age and gender, those patients who used non-glargine plus glargine insulin compared to those using nonglargine insulin alone had a lower rate of cancer but the difference was not significant. However, those using insulin glargine alone had a higher rate of cancer compared to those patients who used non-glargine insulin. This difference was only of borderline statistical significance and only so for breast cancer. The authors attributed this slight increase in risk for breast cancer associated with insulin glargine to allocation bias.
In the second approach, a group of patients (n = 12 852) with definite type 2 diabetes and who received insulin for the first time between January 2002 and 31 December 2005 were investigated. A total of 378 cancers occurred in this group. Overall, the incidence of cancer was no different between the insulin glargine users (regardless of what other type of insulin they used) compared to the users of non-glargine insulin alone. Likewise, the incidence rate of cancer in the glargine-only users was not higher than in users of non-glargine insulin alone. In this cohort, the incidence of breast cancer was not increased in the glargine users compared to the non-glargine users.
The analysis summarising exposure across the entire follow up showed that there was a significantly lower rate of total cancers (HR 0.66, 95% CI: 0.57-0.76) in those receiving any insulin glargine (regardless of what other insulin they used), compared to the non-glargine insulin users. This HR was even lower in subjects who had had an exposure of at least two years. For breast cancer there was a slight but non-significant increase in incidence in glargine-only users compared to non-glargine insulin users. In this study, the insulin glargine-only users at baseline differed substantially as a group from those using non-glargine plus glargine insulin or those using non-glargine insulin alone. The authors concluded that in spite of shortcomings in their study, the results were reassuring that use of insulin glargine was not associated with an increased incidence of cancer. Although their data do not provide complete reassurance, they do not point to unequivocal evidence of harm either.
Summary of findings and recommendations (adapted from EASd
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• The German study found that a patient on insulin glargine was more likely to be diagnosed with cancer than a patient on the same dose of human insulin. This difference was equivalent to one extra case of cancer for every 100 patients taking glargine insulin for one year.
• The Swedish study found no increase in risk of cancer in patients taking glargine along with other types of rapid-acting insulin. Women on glargine alone were twice as likely to be diagnosed with breast cancer. This risk was equivalent to one new case of breast cancer for every 1 000 women treated for one year.
• The UK study found no increase in risk of any cancer including breast cancer between the four insulin regimens studied. Patients on metformin tablets were less likely to be diagnosed with cancer than patients on other forms of treatment. This was also seen when metformin was taken with other tablets or with insulin.
• The Scottish study found a slightly reduced risk of cancer in those patients (who were younger and included patients with type 1 diabetes) who took glargine insulin along with other insulins, compared to those who took only human insulin. The patients who took glargine only (who were older) were more likely to have any form of cancer including breast cancer, although the risk was statistically not significant.
•
The researchers involved in all four studies agreed that these findings were not conclusive since the studies were observational and not clinical trials. The possibility that differences between groups of people were responsible for the different rates of cancer cannot be excluded. Further studies are needed before a final conclusion can be reached.
• Insulin glargine is widely used and was found to be helpful on an individual basis, although clinical trials did not show that it provided better overall glucose control than human insulin in patients with type 2 diabetes. However, some patients with troublesome hypoglycaemia may find it beneficial.
• The EASD does not recommend that patients should stop taking insulin glargine on the basis of evidence presented in these trials. Patients do, however, have the option of using long-acting human insulin or a mixture of short-and longacting human insulin twice a day instead of the once-daily analogue. Especially patients who already have cancer or women with a family history of breast cancer may wish to consider this option.
The American Association of Clinical Endocrinologists (AACE) takes a slightly different view from the EASD.
9 This organisation, representing mainly practicing clinicians, agrees that the evidence presented in the four studies is not sufficient to warrant any firm conclusions. The findings were not consistent and were even contradictory in some respects, the patient populations were not always comparable, and the duration of observation was short. The AACE does not recommend that the use of any insulin should be changed but supports the view that further research is warranted to establish the safety and efficacy of all diabetes therapies. Meanwhile, individual patient concerns should be discussed with their doctors.
The American Diabetes Association (ADA) was even more cryptic in its comments. 10 The ADA simply states that if patients taking insulin glargine consider switching to another form of insulin, these studies make it unclear whether one type of insulin increases the risk of cancer more than other types of insulin. The ADA also recommends that concerned patients should not stop taking their insulin on the basis of these studies but should talk to their doctors.
The EASD, the AACE and the ADA do not suggest the introduction of any cancer screening programme in patients with type 2 diabetes who were exposed to insulin or any form of diabetes therapy over a long period. It is however clear that the relationship between type 2 diabetes, including its therapy, and the risk of cancer, warrants further research. Meanwhile, it may be prudent to emphasise that patients with type 2 diabetes are not only at risk of macro-or microvascular disease but that they have a similar or even increased risk of certain cancers compared with to the non-diabetic population. Patients with type 2 diabetes should at least be offered the standard screening guidelines for commonly occurring cancers.
11 Any remaining concerns individual patients may have regarding the continued used of insulin glargine should be discussed with their doctors. 
Comment from Prof François Bonnici
The recent news alerting the diabetes world to safety concerns regarding primarily insulin glargine, in fact bring to the fore a wider debate, that of increased risk of cancer in patients with type 2 diabetes, and the treatment of diabetes with other insulins and insulin secretagogues. Indeed, there are putative mechanistic explanations of this risk, through high insulin levels and associated changes in the IGF-1 axis accelerating the progression of existing cancer.
How should we react to such disturbing news? The findings of all the quoted studies have to be interpreted with caution. We need an honest, sensible, but prudent response, as reasoned as the one expressed by Smith and Gale and the various international diabetes organisations. Cause for concern, not panic. 1 We would not wish to see a mass withdrawal of effective therapy, an indiscriminate switch to other insulin products, and unwarranted alarm in an already vulnerable population. There is no evidence that insulin, however formulated, directly causes cancer, but pre-clinical and epidemiological indications exist to suggest that high concentrations of insulin, both endogenous and exogenous, may promote its development.
A time for questions then, to futher elucidate aspects of association, causation and effect of confounding factors, through prospective clinical studies on patients with type 2 diabetes and all its forms of therapy.
A time for transparency, accessible information and wise recommendations, including a heightened awareness of the present ravages of long-term, uncontrolled hyperglycaemia, the potentially protective role of metformin, the often-forgotten value on cancer risk reduction of lifestyle measures, healthy diet, exercise and smoking cessation.
A time for prudence for individuals with type 2 diabetes on high insulin doses, those with increased cancer risk or with recent cancer diagnoses, who may wish to discuss with their doctors safe and effective alternative therapies.
There are legitimate causes for concern regarding increased cancer risk in people with type 2 diabetes. The analysis of the available studies is however controversial, the questions at issue are not yet resolved, but the implications are serious. Reassuringly, no such associations have ever been shown in younger type 1 diabetes patients who most benefit from insulin analogue therapy.
FRANÇOIS BONNICI Editorial Board member Emeritus Professor, Faculty of Health Sciences, University of Cape Town
reply from dr Navin Singh
Four registry analyses were published on the website of Diabetologia, the journal of the European Association for the Study of Diabetes (EASD) on 26 June 2009, discussing a hypothetical link between treatment with insulin glargine and cancer. [1] [2] [3] [4] All four studies are retrospective observational registries from different populations (Germany, Sweden, Scotland, UK). A possible dose-response association between insulin glargine and cancer was observed in the German study but not in the Swedish, Scottish, or UK studies. A possible association between insulin glargine and breast cancer risk was found in the Swedish study but not consistently in the others.
Common limitations and weaknesses of observational studies can be identified in all of these registries. Overall, results from the four studies were inconsistent. No definitive conclusion can be drawn regarding a possible causal relationship between insulin glargine use and the occurrence of malignancies.
Clinical studies do not indicate an association between insulin glargine and cancer. This includes data from clinical studies covering over 70 000 patients. In controlled trials in 10 465 people with type 1 or type 2 diabetes, there was no difference in the incidence of malignancies in patients treated with insulin glargine versus comparators, including NPH insulin.
5
In a five-year controlled clinical trial in 1 017 patients with type 2 diabetes, the overall rate of malignancies was similar in the insulin glargine and NPH groups [insulin glargine 23 patients (4.5%), NPH 32 (6.4%)]. The number of patients with breast cancer was also similar (insulin glargine, three; NPH, five). This report is now published in Diabetologia.
